Louis B. Nabors
Affiliations: | Neurobiology | University of Alabama, Birmingham, Birmingham, AL, United States |
Area:
Neuroscience Biology, Molecular BiologyGoogle:
"Louis Nabors"Mean distance: 53433
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Bastola S, Pavlyukov MS, Yamashita D, et al. (2020) Glioma-initiating cells at tumor edge gain signals from tumor core cells to promote their malignancy. Nature Communications. 11: 4660 |
| Reardon DA, Desjardins A, Vredenburgh JJ, et al. (2020) Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Lobbous M, Bernstock JD, Coffee E, et al. (2020) An Update on Neurofibromatosis Type 1-Associated Gliomas. Cancers. 12 |
| Lamb LS, Gibbs S, Pillay T, et al. (2020) Phase I trial of drug resistant immunotherapy: A first-in-class combination of MGMT-modified γδ t cells and temozolomide chemotherapy in newly diagnosed glioblastoma multiforme. Journal of Clinical Oncology. 38 |
| Romo CG, Alexander BM, Agar N, et al. (2020) Intratumoral drug distribution of adavosertib in patients with glioblastoma: Interim results of phase I study. Journal of Clinical Oncology. 38: 2568-2568 |
| Lim M, Ye X, Piotrowski AF, et al. (2020) Updated safety phase I trial of anti-LAG-3 alone and in combination with anti-PD-1 in patients with recurrent GBM. Journal of Clinical Oncology. 38: 2512-2512 |
| Hayward EN, Yang X, Filippova N, et al. (2020) Abstract 3335: Characterization and analysis of the complement immune system in glioblastoma (GBM) Immunology. 80: 3335-3335 |
| Fathallah-Shaykh HM, DeAtkine A, Coffee E, et al. (2019) Diagnosing growth in low-grade gliomas with and without longitudinal volume measurements: A retrospective observational study. Plos Medicine. 16: e1002810 |
| Kaley T, Nabors LB. (2019) Management of Central Nervous System Tumors. Journal of the National Comprehensive Cancer Network : Jnccn. 17: 579-582 |
| Lim M, Ye X, Piotrowski AF, et al. (2019) Updated phase I trial of anti-LAG-3 or anti-CD137 alone and in combination with anti-PD-1 in patients with recurrent GBM. Journal of Clinical Oncology. 37: 2017-2017 |